ResearchPoint & Azaya Therapeutics, Inc. Announce First Patient Enrolled in Phase I Clinical Study
Published: Jan 26, 2010
AUSTIN, Texas--(BUSINESS WIRE)--ResearchPoint and Azaya Therapeutics, Inc. are proud to announce the study initiation and enrollment of the first patient in the phase I clinical study of ATI-1123, a new formulation of docetaxel. ATI-1123 has the same active ingredient as the FDA approved drug Taxotere® (docetaxel). The study is being conducted at two premier Texas cancer centers in patients with advanced solid tumors. The open-label, dose escalation study is being managed by ResearchPoint, a leading Texas-based CRO with extensive oncology trial experience.